Oncode Scientific Sdn Bhd

𝗔𝘀 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗯𝗲𝗰𝗼𝗺𝗲𝘀 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗶𝗻𝗴𝗹𝘆 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘀𝗲𝗱, 𝘁𝗵𝗲 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗮𝗻𝗱 𝗱𝗲𝗽𝘁𝗵 𝗼𝗳 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗽𝗹𝗮𝘆 𝗮 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗿𝗼𝗹𝗲 𝗶𝗻 𝗴𝘂𝗶𝗱𝗶𝗻𝗴 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀.

On 21st May 2026, Oncode had the privilege of conducting a CME session with the Respiratory Department at Hospital Al-Sultan Abdullah, UiTM Puncak Alam, on the topic "Advancing Lung Cancer Care Through Molecular Testing."

The session provided an in-depth comparison of PCR and NGS technologies, highlighting their respective strengths in the molecular profiling of lung cancer for accurate diagnosis and targeted treatment selection.

We also introduced our latest upgraded NGS panels, discussing their clinical applications and how expanded genomic coverage can support more comprehensive patient management.

A key focus of the discussion was the importance of robust validation processes and quality control frameworks, ensuring the precision, sensitivity, and reliability required in molecular diagnostics.

The session concluded with engaging discussions around real-world case studies, showcasing significant findings uncovered through NGS testing and the growing role of tissue and liquid biopsy applications in modern cancer care.

Thank you to the Respiratory Department team at Hospital Al-Sultan Abdullah, UiTM Puncak Alam, for the insightful exchange and shared commitment to advancing precision oncology.

𝗧𝗵𝗲 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 𝗰𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆 𝗼𝗳 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗲𝗺𝗮𝗻𝗱𝘀 𝗺𝗼𝗿𝗲 𝗰𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀.

On 11th May 2026, Oncode Laboratory hosted an impactful CME session with the Respiratory Medicine and Pathology Units at Hospital Tuanku Jaafar Seremban (HTJS). The room was packed with forward-thinking specialists, medical officers, and allied health professionals all focused on one critical goal: 𝗼𝗽𝘁𝗶𝗺𝗶𝘀𝗶𝗻𝗴 𝘁𝗶𝘀𝘀𝘂𝗲 𝘀𝗮𝗺𝗽𝗹𝗲𝘀 𝗳𝗼𝗿 𝗡𝗼𝗻-𝗦𝗺𝗮𝗹𝗹 𝗖𝗲𝗹𝗹 𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 (𝗡𝗦𝗖𝗟𝗖) 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀.

𝗛𝗲𝗿𝗲 𝗮𝗿𝗲 𝘁𝗵𝗲 𝗸𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀 𝗳𝗿𝗼𝗺 𝗼𝘂𝗿 𝗱𝗲𝗲𝗽 𝗱𝗶𝘃𝗲:

🔬 𝗣𝗖𝗥 𝘃𝘀. 𝗡𝗚𝗦:
We broke down the distinct clinical roles of both technologies, focusing on how Next-Generation Sequencing (NGS) uncovers actionable biomarkers that traditional Polymerase Chain Reaction (PCR) might miss, directly impacting targeted therapy decisions.

🩺 𝗘𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗔𝗰𝗰𝗲𝘀𝘀:
We highlighted our subsidised diagnostic program in partnership with AstraZeneca. Crucially, we discussed how having both tissue and liquid biopsy options in the clinical toolkit gives clinicians the flexibility to choose the right tool at the right time—ensuring tissue-scarce patients don't miss out on vital molecular profiling.

📋 𝗙𝗿𝗼𝗺 𝗟𝗮𝗯 𝘁𝗼 𝗕𝗲𝗱𝘀𝗶𝗱𝗲:
Through real-world case studies, we walked through practical, seamless workflows—from initial sample collection and rebiopsy strategies to test ordering—ensuring clinicians can implement these insights immediately without operational friction.

A huge thank you to the HTJS Respiratory and Pathology teams for their engaging insights and shared dedication to pushing the boundaries of precision thoracic oncology. Together, we are making broader genomic profiling the standard, not the exception.

𝗙𝗿𝗼𝗺 𝘀𝗮𝗺𝗽𝗹𝗲 𝗽𝗿𝗲𝗽𝗮𝗿𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀, 𝗲𝘃𝗲𝗿𝘆 𝘀𝘁𝗲𝗽 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 𝗶𝗻 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆.

On 20 April 2026, Oncode had the privilege of conducting a CME session with the Department of Internal Medicine, Hospital Seri Manjung, on the topic "NGS in Cancer: From Biomarkers to Treatment Decision."

The session explored the fundamentals of NGS testing, its growing role in precision oncology, and the importance of proper pre-analytical sample handling and preparation to ensure accurate and reliable results.

We also fostered valuable discussions between physicians and laboratory teams, aligning on best practices that enhance test quality, clinical interpretation, and ultimately, patient care.

Thank you to the Hospital Seri Manjung team for the engaging exchange and shared commitment to advancing precision medicine.

A time for quiet reflection and gentle awareness.

Wishing you peace, clarity, and a sense of wellbeing that stays. 🕊️

Selamat Hari Raya Haji.

Most people don’t panic when they see it once.
They assume it’s dehydration, infection, or “it’ll go away.”
𝗕𝘂𝘁 𝗯𝗹𝗼𝗼𝗱 𝗶𝗻 𝘂𝗿𝗶𝗻𝗲 — 𝗲𝘃𝗲𝗻 𝗼𝗻𝗰𝗲 — 𝘀𝗵𝗼𝘂𝗹𝗱 𝗻𝗲𝘃𝗲𝗿 𝗯𝗲 𝗶𝗴𝗻𝗼𝗿𝗲𝗱‼️

𝗕𝗹𝗮𝗱𝗱𝗲𝗿 𝗰𝗮𝗻𝗰𝗲𝗿 𝗼𝗳𝘁𝗲𝗻 𝘀𝗵𝗼𝘄𝘀 𝗲𝗮𝗿𝗹𝘆 𝘀𝗶𝗴𝗻𝘀 𝗹𝗶𝗸𝗲:
✔ Blood in urine
✔ Frequent urination
✔ Pain or burning sensation

💡The problem?
𝗧𝗵𝗲𝘀𝗲 𝘀𝘆𝗺𝗽𝘁𝗼𝗺𝘀 𝗮𝗿𝗲 𝗲𝗮𝘀𝘆 𝘁𝗼 𝗱𝗶𝘀𝗺𝗶𝘀𝘀.

🩺Early detection makes a significant difference in treatment outcomes.
If something feels off, don’t wait for it to repeat.
𝗖𝗵𝗲𝗰𝗸 𝗲𝗮𝗿𝗹𝘆. 𝗥𝘂𝗹𝗲 𝗶𝘁 𝗼𝘂𝘁.

As precision medicine continues to redefine oncology, the ability to translate 𝗴𝗲𝗻𝗼𝗺𝗶𝗰 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗶𝗻𝘁𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗰𝘁𝗶𝗼𝗻 has never been more important.

On 8 May 2026, Oncode had the privilege of conducting a CME session with the 𝗢𝗯𝘀𝘁𝗲𝘁𝗿𝗶𝗰𝘀 & 𝗚𝘆𝗻𝗮𝗲𝗰𝗼𝗹𝗼𝗴𝘆 𝗗𝗲𝗽𝗮𝗿𝘁𝗺𝗲𝗻𝘁 𝗮𝘁 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗠𝗮𝗹𝗮𝘆𝗮 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗖𝗲𝗻𝘁𝗿𝗲 (𝗨𝗠𝗠𝗖), focusing on the evolving role of 𝗡𝗲𝘅𝘁-𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗶𝗻𝗴 (𝗡𝗚𝗦) in gynecologic cancer management.

A key discussion centred on the importance of 𝗛𝗼𝗺𝗼𝗹𝗼𝗴𝗼𝘂𝘀 𝗥𝗲𝗰𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗗𝗲𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 (𝗛𝗥𝗗) 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 in guiding targeted therapies such as 𝗣𝗔𝗥𝗣 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 for 𝗢𝘃𝗮𝗿𝗶𝗮𝗻, 𝗙𝗮𝗹𝗹𝗼𝗽𝗶𝗮𝗻 𝗧𝘂𝗯𝗲, 𝗮𝗻𝗱 𝗣𝗿𝗶𝗺𝗮𝗿𝘆 𝗣𝗲𝗿𝗶𝘁𝗼𝗻𝗲𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿𝘀 — reinforcing how molecular profiling is shaping more personalised treatment pathways.

We also shared how our collaboration with 𝗔𝘀𝘁𝗿𝗮𝗭𝗲𝗻𝗲𝗰𝗮 helps improve 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗮𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆 through subsidised HRD testing, ensuring advanced genomic insights remain within reach for more patients.

Beyond HRD, the session explored Oncode’s expanding precision oncology portfolio, including our 𝗘𝗻𝗱𝗼𝗺𝗲𝘁𝗿𝗶𝗮𝗹 𝗖𝗮𝗻𝗰𝗲𝗿 𝗡𝗚𝗦 𝗣𝗮𝗻𝗲𝗹 and 𝗣𝗮𝗻-𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗣𝗮𝗻𝗲𝗹, designed to uncover clinically actionable insights across diverse tumour profiles.

At Oncode, we remain committed to supporting clinicians with 𝗵𝗶𝗴𝗵-𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗮𝗹𝗶𝗴𝗻𝗲𝗱 𝘄𝗶𝘁𝗵 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝘀 — empowering more confident, data-driven cancer care.

Thank you to the UMMC O&G team for the meaningful discussions and shared commitment to advancing precision medicine in women’s health.

Some care is never loud.
But somehow, everything is always taken care of.

The quiet reminders.
The constant presence.
The strength that holds everything together without asking for recognition.

To every mother,
thank you for all the care we often forget to say out loud.
Wishing you love, health, and happiness🩵

Happy Mother’s Day🫶🏻

Better cancer treatment decisions start with a precise molecular understanding of the tumour.

On 29th April 2026, Oncode had the privilege of collaborating with the dedicated 𝗥𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝘁𝗲𝗮𝗺 𝗮𝘁 𝗛𝗼𝘀𝗽𝗶𝘁𝗮𝗹 𝗔𝗺𝗽𝗮𝗻𝗴 to explore the rapidly evolving landscape of Next-Generation Sequencing (NGS) in lung cancer care.

Our session went beyond the technology, focusing on how broader genomic profiling—utilising 𝘁𝗶𝘀𝘀𝘂𝗲 𝗮𝗻𝗱 𝗹𝗶𝗾𝘂𝗶𝗱 𝗯𝗶𝗼𝗽𝘀𝗶𝗲𝘀—unlocks critical molecular insights that drive personalised, targeted therapeutic decisions.

Together, we navigated the nuances of selecting the most clinically appropriate molecular tests, 𝗯𝗮𝗹𝗮𝗻𝗰𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝗼𝗹𝗲𝘀 𝗼𝗳 𝗯𝗼𝘁𝗵 𝗡𝗚𝗦 𝗮𝗻𝗱 𝗣𝗖𝗥, to ensure every patient is matched with the optimal treatment strategy. A highlight of our engagement was a deep dive into 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗢𝗻𝗰𝗼𝗱𝗲 𝗰𝗮𝘀𝗲 𝘀𝘁𝘂𝗱𝗶𝗲𝘀, demonstrating exactly how these actionable genomic insights directly shape patient treatment plans at the clinical frontline.

A sincere thank you to the Hospital Ampang team for a dynamic exchange of ideas and a shared commitment to advancing precision respiratory oncology in Malaysia.

Behind every breakthrough🔬,
there is work — seen and unseen.

Progress doesn’t happen all at once.
It’s built through consistent effort, day after day.

Today, we recognise the dedication that keeps everything moving forward 💪🏻

Happy Labour Day!

Head and neck cancers are among the most preventable — yet they remain frequently diagnosed at advanced stages.

Persistent symptoms such as a sore throat, unexplained hoarseness, difficulty swallowing, or a lump in the neck are often attributed to minor conditions. When left unaddressed, delayed attention can lead to diagnosis at more advanced stages, where treatment becomes more complex.

To***co use, alcohol consumption, and HPV infection account for the majority of cases — many of which are preventable with the right awareness and timely action.

Advances in molecular diagnostics now allow clinicians to better classify these cancers, enabling more precise and personalised treatment strategies.

Awareness is the first step.
Timely action is what makes the difference.